Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
US6569616B1 · kind B1 · utility
4Cited by
16References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 28, 2000 |
| Grant date | May 27, 2003 |
| Priority date | — |
| Expiry date | Jul 28, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of designing a new anti-CMV drug is disclosed. In one embodiment, the invention comprises (a) analyzing the binding of glycoprotein O to a glycoprotein O receptor and (b) designing a candidate drug that would competitively interfere with glycoprotein O binding to glycoprotein O receptor and (c) showing that the candidate drug competitively inhibits glycoprotein O binding to glycoprotein O receptor. A method of screening anti-CMV drugs, a vaccine effective to diminish CMV infection, and a method of diminishing CMV infection are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.